Poolbeg Pharma (POLB), a clinical stage infectious disease pharmaceutical company, announced its unaudited interim results for the six months to 30 June 2022.
The company said it is entering a very exciting phase in its development with a number of near-term value inflection points expected before year end. This includes the initial results from our LPS human challenge trial for our severe influenza treatment, POLB 001, after which we will seek to out-licence to pharma and biotech companies, generating revenues from upfront payment and downstream milestones and royalties. In addition, the outputs from our RSV and influenza Artificial Intelligence Programmes are expected by the end of 2022 and in Q2 2023 respectively.
Feedback (FDBK), the specialist clinical infrastructure company, announced that it has been awarded a twelve-month contract to provide its CDC solution in order to facilitate an extension of the current CDC pilot in Sussex to further GP practices and to enable the adoption of further clinical pathways. The discounted contract is valued at £450,000 and covers the period from 31st March 2022 when the pilot MOU formally ended.
Chaarat Gold (CGH), the AIM-quoted gold mining company with an operating mine in Armenia, and assets at various stages of development in the Kyrgyz Republic, announced that it will release its H1 2022 financial update on Thursday, 8th September 2022. Following the release, Chaarat will host an investor and analyst presentation on the H1 2022 results on Thursday, 8th September 2022, at 9.00 am BST.
Pantheon Resources (PANR), the AIM listed oil and gas company, provides an operational update. Th company said activities at Alkaid #2 are on schedule and it looks forward to flow testing operations commencing. Upgrading facilities to a larger capacity was a sensible decision, giving the flexibility and freedom to bring multiple wells into production at the Alkaid #2 location in due course.
Blencowe Resources (BRES) announced that is has terminated its agreement with SIPA Resources with respect to the Akelikongo nickel project. The company has instead targeted bringing Orom-Cross into initial production before the end of 2023, in order to commence the pre-qualification process of selling end product as concentrate into offtake parties.
Synergia Energy (SYN) (formerly named Oilex Ltd) updated with respect to its operations in India. The company said it has contracted a workover rig from Aakash Exploration Services Ltd for mobilisation to the Cambay C-77H wellsite on 12 September 2022. The primary operation will be to re-install the production tubing but additional tasks will be to remove the frac tree and re-install the production Christmas tree.
Orosur Mining (OMI) announced an update on the progress of exploration activities at the Company’s flagship Anzá Project in Colombia. The company said results from PEP001 largely speak for themselves. To return such a result for the first hole in the first drill campaign in an untouched area is a spectacular demonstration of the potential of the Anzá Project.
Contango Holdings (CGO), the London listed natural resource company, provided an update on its continuing coking coal and coke product tests. The company said the latest set of results from its ongoing coking coal and coke tests have reaffirmed the attractive characteristics of Lubu. Earlier this year it entered into an offtake with AtoZ Investments for 10,000t per month of washed coking coal, which is expected to deliver first revenue by the end of the calendar year.
Oracle Power (ORCP), the international natural resources project developer, advised shareholders of its nomination by the Korea Trade-Investment Promotion Agency to develop a strategy to register carbon credits within Pakistan. The intention of this process is to eventually trade carbon credits under the Internationally Transferred Mitigation Outcomes mechanism in accordance with Article 6 of the Paris Agreement, as ratified at COP26 in November 2021.
Ondine Biomedical (OBI) announced that its Phase 2 BENEFIT-APDT clinical trial met the primary endpoint of bacterial load reduction after nasal photodisinfection. Results from the study showed that nasal photodisinfection eliminated or significantly decreased S. aureus in 92% of carriers (P<0.001) immediately after treatment. There were no reportable adverse events or unexpected safety issues; treatment was found to be safe and well tolerated. The company said concluding its Phase 2 trial is a key milestone that satisfies its IPO commitment and puts it firmly on the path towards completing the US FDA regulatory process.
Cellular Goods (CBX), a UK-based wellness company, announced the publication of a new white paper, ‘The 5 A’s of Cannabinoid Skincare’, which explores the benefits cannabinoids, namely cannabidiol and cannabigerol, can have for the skin as powerhouse ingredients that provide a multitude of benefits for skincare applications. Cellular Goods refers to these benefits as the ‘5 A’s of Cannabinoid Skincare’ owing to cannabinoids’ strong ageing prevention, anti-inflammatory, antioxidant, anti-bacterial, and anti-melanogenesis properties.
Echo Energy (ECHO), the Latin American focussed full cycle energy company, announced its audited results for the twelve months ended 31 December 2021. The company said that with progress made on the ground operationally and supported by much higher prevailing commodity prices and premium pricing in gas contracts, the recently announced comprehensive restructuring and strengthening of its balance sheet, once completed, will ensure it has much firmer foundations for the business financially.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
